Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995817 | 0.80 | L3MBTL1 (0.42) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL4425197 | 0.75 | HSD17B10 (0.47) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL30071242 | 0.70 | FFAR2 (0.47) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL4410599 | 0.70 | FFAR2 (0.47) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL6361625 | 0.70 | SMN1; SMN2 (0.47) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL18900166 | 0.69 | SORT1 (0.50) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL4551723 | 0.69 | CA1 (0.47) | ADORA3ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL9948612 | 0.69 | ADORA3 (0.40) | ADORA3ADORA1ADORA2AADORA2BRAB9A | |
| SCHEMBL4551457 | 0.68 | SMN1; SMN2 (0.65) | ADORA3ADORA1ADORA2AADORA2BRAB9A | |
| SCHEMBL30071250 | 0.68 | GAA (0.76) | HSD17B10RAB9ANPC1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| EP-0269859-B2 | Pyrazolotriazine compounds | OTSUKA PHARMA CO LTD (JP) | 1995-10-18 | — | — | EP | disclosed |
| CN-1017708-B | METHOD FOR PREPARATION OF PYRAZOLOTRIAZINE COMPOUNDS | OTSUKA CHEMICAL CO LTD (JP) | 1992-08-05 | — | — | CN | disclosed |
| US-4824834-A | TREATING GOUT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0269859-A2 | Pyrazolotriazine compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| CN-87107217-A | Method for preparation of pyrazolotriazine compounds | — | 1988-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | ADORA3 636/4885ADORA1 639/4885ADORA2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.